ReviewNature reviews. Nephrology2010
HDL metabolism and activity in chronic kidney disease.
Review in Nature reviews. Nephrology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 155 citations in OpenAlex.
- Statins Have an Anti-Inflammation in CKD Patients: A Meta-Analysis of Randomized Trials.BioMed research international · 2022Pooled it
- Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?Clinical pharmacokinetics · 2013Trial
- Vitamin E tocotrienol supplementation improves lipid profiles in chronic hemodialysis patients.Vascular health and risk management · 2013Trial
- Article
- Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials.American journal of preventive cardiology · 2026Article
- Review
- Atherogenic index of plasma predicts progression of diabetic kidney disease.Frontiers in medicine · 2026Article
- Prognostic value of serum total bilirubin-lipid ratios in patients with IgA nephropathy.Frontiers in endocrinology · 2026Article
- Association between neutrophil-to-HDL cholesterol ratio and the risk of gout or hyperuricemia: evidence from NHANES 2007-2018.European journal of medical research · 2025Article
- Serum High-Density Lipoprotein Cholesterol Levels and the Risk of Kidney Function Decline: The Japan Specific Health Checkups (J‑SHC) Study.Journal of atherosclerosis and thrombosis · 2025Article
- High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?International journal of molecular sciences · 2025Review
- MHR Was Associated with Hyperuricemia Risk in Patients with Type 2 Diabetes Mellitus: The Mediating Effect of Body Mass Index.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Association of Three Composite Inflammatory and Lipid Metabolism Indicators With Cardiovascular-Kidney-Metabolic Syndrome: A Cross-Sectional Study Based on NHANES 1999-2020.Mediators of inflammation · 2025Article
- The association between monocyte to high-density lipoprotein cholesterol ratio and chronic kidney disease in a Chinese adult population: a cross-sectional study.Renal failure · 2024Article
- Combinative predictive effect of left ventricular mass index, ratio of HDL and CRP for progression of chronic kidney disease in non-dialysis patient.International urology and nephrology · 2024Article
- SARS-CoV-2 induced HDL dysfunction may affect the host's response to and recovery from COVID-19.Immunity, inflammation and disease · 2023Review
- Article
- Bibliometric visualization analysis of gut-kidney axis from 2003 to 2022.Frontiers in physiology · 2023Review
- Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is associated with development of atherosclerosis and premature death from cardiovascular disease. The predisposition of patients with CKD to atherosclerosis is driven by inflammation, oxidative stress and dyslipidemia, all of which are common features of this condition. Markers of dyslipidemia in patients with advanced CKD are impaired clearance and heightened oxidation of apolipoprotein-B-containing lipoproteins and their atherogenic remnants, and a reduction of the plasma concentration, antioxidant, and anti-inflammatory properties of high-density lipoprotein (HDL). Studies in animal models of CKD indicate that the disease promotes lipid accumulation in the artery wall and kidney, leading to atherosclerosis, glomerulosclerosis and tubulointerstitial injury. These effects seem to be mediated by an increased cellular influx of lipids, elevated cellular production and reduced cellular catabolism of fatty acids, and impaired antioxidant, anti-inflammatory and reverse lipid transport properties of HDL. Available pharmacological therapies have been largely ineffective in ameliorating oxidative stress, inflammation, HDL deficiency and/or dysfunction, and the associated atherosclerosis and cardiovascular disease in patients with end-stage renal disease. This Review aims to provide an overview of the mechanisms and consequences of CKD-induced HDL deficiency and dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.